FDA Grants Fast Track Status to Biliary Cancer Drug
The designation aims to accelerate the review of a new treatment for adults with advanced biliary tract cancer.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Do you believe FDA fast-track designations for experimental cancer drugs effectively help patients get better care?
The FDA has granted Fast Track Designation to opamtistomig, an investigational drug for adults with advanced or metastatic biliary tract cancer. This regulatory step aims to expedite the development and review of a therapy designed to treat this aggressive form of cancer.
Why it matters
Biliary tract cancer is characterized by a low 5-year survival rate of less than 5 percent, reflecting an urgent unmet need for new treatment options. This designation allows for more frequent interactions with federal regulators to discuss evidence and potential registration pathways.
The drug is currently in a Phase II trial, following a Phase I/IIa study that enrolled 175 participants to evaluate safety and antitumor activity. While findings from the Phase I/IIa study are pending formal publication, the current investigation represents a preliminary clinical effort.
The players
Leads Biolabs
A biotechnology company headquartered in Nanjing, China, focused on the development of antibody-based cancer therapies.
FDA
The United States federal agency responsible for regulating medical products and overseeing the clinical registration process for new drugs.
The details
Opamtistomig is a bispecific antibody engineered to target both PD-L1 and 4-1BB. By blocking the PD-L1 pathway, the drug prevents cancer cells from evading the immune system, while simultaneously activating 4-1BB to stimulate T-cell responses within the tumor microenvironment. This dual-action approach is intended to enhance the body's natural ability to identify and attack malignant biliary cells.
Timeline
2022: The Phase I/IIa study of opamtistomig was initiated.
2024: Global incidence reached 419,100 new biliary tract cancer cases.
April 2026: The Phase II study advanced into its expansion phase.
October 12, 2026: The FDA granted Fast Track Designation to opamtistomig.
Health Landscape
The standard of care for advanced biliary tract cancer remains limited, with historical objective response rates near 30 percent for standard chemotherapy. Opamtistomig sits within a growing class of bispecific antibodies attempting to improve these outcomes by combining immune checkpoints with costimulation.
This development does not yet affect current treatment options, as the drug is still undergoing clinical study and is not available for prescription. Patients interested in how new clinical trials might fit into their care plan should have a discussion with their oncologist.
The takeaway
While this is a preliminary step in the regulatory process, it underscores the ongoing search for better therapies for advanced biliary tract cancers. Patients and families can monitor clinical trial databases for updates on the expansion phase of the study to understand potential future access.
Further reading
For more information on current treatment landscapes, explore our Cancer section.
Source note: This article includes information reported by Drugs.
Live Poll
Do you believe FDA fast-track designations for experimental cancer drugs effectively help patients get better care?
